Medsenic
Medsenic is a private Paris-based drug development company founded in 2010. Led by co-founders François Rieger and Véronique Pomi, the firm operates with 1-10 employees and expanded its pipeline via its 2022 acquisition of Bone Therapeutics.
- Company typePrivate
- Founded2010
- HeadquartersParis, France
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medsenic does
Medsenic is a private drug development company headquartered in Paris, France, founded in 2010. The firm operates with a small team of 1-10 employees and is led by co-founders François Rieger (Chief Executive Officer & President) and Véronique Pomi (Chief Operating Officer). As a clinical-stage developer, Medsenic's pipeline and capabilities were significantly expanded through its October 2022 acquisition of Bone Therapeutics, a bone cell therapy company, though no specific products, therapeutic indications, or pipeline assets are publicly disclosed in the available data.
The company's only documented funding event was a February 2018 round of approximately $2.48 million, led by Investisseurs & Partenaires with participation from Cap Innov'Est and FaDièse. No subsequent funding rounds are recorded, and the company's website is currently in scheduled maintenance mode, limiting access to product, clinical, or commercial disclosures. The business model is not publicly articulated, but the headcount, funding scale, and absence of disclosed revenue are consistent with a pre-commercial drug developer relying on R&D funding and asset-based value creation rather than product sales.
Given the limited public footprint, Medsenic's strategic value appears to reside primarily in the clinical-stage assets and IP absorbed via the Bone Therapeutics transaction. The lack of publicly available product information, customer references, pricing, partnerships, or revenue signals represents a significant data gap that constrains any deeper commercial or competitive analysis.
Medsenic firmographics
Firmographics- Name
- Medsenic
- Legal name
- Medsenic
- Website
- https://medsenic.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medsenic is a private Paris-based drug development company founded in 2010. Led by co-founders François Rieger and Véronique Pomi, the firm operates with 1-10 employees and expanded its pipeline via its 2022 acquisition of Bone Therapeutics.
- Ownership category
- akta.pro rank
Medsenic industry classification
Industry- Product category
- Pharmaceutical Drug Development
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Medsenic is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
Medsenic business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Medsenic product offering
Product offeringCore offering
Medsenic is a private drug development company headquartered in Paris, France. The company focuses on pharmaceutical research and development, building its therapeutic pipeline through internal R&D and strategic acquisitions, including the 2022 acquisition of Bone Therapeutics to expand into bone-related therapeutics.
Differentiator
Problem solved
Functional benefit
Companies that use Medsenic
Customer profileIdeal customer profiles1 record
Medsenic technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Medsenic partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
Medsenic competitors and assessment
Company assessmentDirect peers
- Bone Therapeutics: Belgian cell-therapy biotech that Medsenic acquired in 2022, formerly focused on bone disease and regenerative medicine. Its prior clinical assets and IP are now integrated into Medsenic, making the acquisition target itself the closest historical peer.
- Innate Pharma: France-headquartered (Marseille) clinical-stage biotech developing immuno-oncology and immunology therapies. Comparable as a small French innovator-drug developer with specialty-pharmaceutical positioning.
- DBV Technologies: Paris-based clinical-stage biotech developing epicutaneous immunotherapy for allergies and autoimmune-related conditions. Comparable as a French specialty-pharmaceutical developer targeting immune-mediated diseases.
- Abivax: French Paris-based clinical-stage biotech developing small-molecule therapies for chronic inflammatory diseases. Comparable as a small French innovator-drug developer targeting specialty autoimmune/inflammatory indications with a lean team.
- Valneva: France-headquartered specialty vaccine company developing prophylactic vaccines for infectious diseases. Comparable French specialty-innovator pharmaceutical with a small-team, focused-portfolio model.
- OSE Immunotherapeutics: French clinical-stage biotech developing first-in-class immunotherapies for autoimmune diseases and immuno-oncology. Comparable French specialty-pharma innovator with autoimmune focus and Paris-area presence.
- GenSight Biologics: Paris-listed clinical-stage biotech developing gene therapies for neurodegenerative diseases of the eye and CNS. Comparable as a French, small-employee-count innovator-drug developer focused on specialty indications.
- Inventiva: French biopharmaceutical company developing oral small-molecule therapies for metabolic, fibrotic and autoimmune diseases. Comparable geography (France), innovator-pharmaceutical model, and specialty-disease focus.
Emerging players
- ImCheck Therapeutics: French (Marseille) clinical-stage biotech developing first-in-class gamma-delta T cell-based immunotherapies for cancer and autoimmune disease. Comparable geography and drug-development innovation model, with broader oncology focus.
Others
- TxCell (acquired by Sangamo Therapeutics): French cell-therapy biotech formerly listed in Paris that developed antigen-specific regulatory T-cell therapies for autoimmune and inflammatory diseases. Closest historical European peer in cell-therapy for autoimmunity, now operating within Sangamo.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Medsenic social profiles
Digital presenceMedsenic financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medsenic leadership team
Management profileNumber of profiles
Profiles2 records
Medsenic funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medsenic M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medsenic
What does Medsenic do?
Medsenic is a private drug development company headquartered in Paris, France. The company focuses on pharmaceutical research and development, building its therapeutic pipeline through internal R&D and strategic acquisitions, including the 2022 acquisition of Bone Therapeutics to expand into bone-related therapeutics.
When was Medsenic founded?
Medsenic was founded in 2010. It employs 1 to 10 people.
Where is Medsenic based?
Medsenic is headquartered in Paris, France, in the Europe region.
Who are Medsenic's main competitors?
Direct peers on record are Bone Therapeutics, Innate Pharma, DBV Technologies, Abivax, Valneva, OSE Immunotherapeutics, GenSight Biologics and Inventiva. ImCheck Therapeutics is listed as an emerging player. TxCell (acquired by Sangamo Therapeutics) is listed as an others.
Does Medsenic have an API?
No public API is recorded for Medsenic.
What industry is Medsenic in?
Medsenic's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.